Omecamtiv Mecarbil

Omecamtiv mecarbil is a cardiac myosin activator being tested by Cytokinetics in COMET-HF (NCT06736574), a Phase 3 trial enrolling 1,800 patients with chronic heart failure and severely reduced ejection fraction [1]. The drug already has history. GALACTIC-HF, the first registrational trial in 8,256 patients with heart failure and reduced ejection fraction (HFrEF), hit its primary endpoint of time to cardiovascular (CV) death or heart failure event with a hazard ratio of 0.92, but the FDA issued a Complete Response Letter on 28 February 2023 arguing the effect size did not translate into a clinically convincing benefit and that an additional confirmatory trial would be required [2][3]. COMET-HF is that second trial, narrowed to the sickest patients where GALACTIC-HF's subgroup signal was strongest. This matters because omecamtiv is the only cardiac myosin activator in late development, and if it works, it opens a new mechanistic class for a condition where the standard four-drug regimen still leaves substantial residual mortality. If it fails again, the mechanism is probably done as a commercial opportunity.

Novel small molecule, never approved anywhere. The ChEMBL record (CHEMBL1800955) and UNII (2M19539ERK) are stable, and the WHO assigned ATC code C01CX10 under cardiac stimulants excluding glycosides [4]. Phase 3 recruiting as of late 2025. Cytokinetics regained worldwide rights from Amgen in 2020 after Amgen walked away following mixed Phase 2 data, and the drug is now Cytokinetics' second major asset behind aficamten (approved 2025 for obstructive hypertrophic cardiomyopathy, HCM). Note that aficamten is a cardiac myosin inhibitor targeting the same protein family (beta-cardiac myosin, MYH7) but with opposite pharmacology and a different indication, so it establishes regulatory precedent for drugging cardiac myosin without clearing a path for omecamtiv specifically. The FDA's 28 February 2023 Complete Response Letter was the pivotal setback: regulators acknowledged GALACTIC-HF met statistical significance but concluded the magnitude of benefit was insufficient and explicitly required an additional efficacy trial, a rare and consequential rebuke for a trial that hit its endpoint [3]. No breakthrough therapy, fast track, orphan, or priority review designation has been disclosed for the current program. Expected readout from COMET-HF is around 2028, based on the enrollment target and typical event accrual for a composite cardiovascular endpoint. Cytokinetics' company revenue was approximately $200M in the most recent fiscal year, driven entirely by early aficamten uptake; omecamtiv contributes nothing yet [5].

Heart muscle contracts when tiny motor proteins called myosins grab onto filaments of another protein, actin, and pull. In heart failure with reduced ejection fraction (HFrEF), those contractions are too weak and the heart cannot push enough blood out with each beat. Omecamtiv mecarbil binds directly to cardiac myosin (encoded by MYH7, the gene for the heart's main contractile motor) and shifts more myosin heads into a force-producing state, so each beat is stronger and longer without changing heart rate [6]. The important contrast is with older inotropes like dobutamine and milrinone, which boost contractility by raising calcium and cAMP inside heart cells. That approach increases arrhythmias and oxygen demand, which is why those drugs shorten life expectancy outside acute settings. Omecamtiv does none of that, which is why it has drawn interest for 15 years. The genetics are supportive but complicated. MYH7 mutations cause hypertrophic and dilated cardiomyopathy, and Open Targets scores MYH7 at 0.895 for hypertrophic cardiomyopathy and 0.77 for broader cardiomyopathy [7]. Loss-of-function genetics validate the gene as central to cardiac contraction, but they do not directly predict that pharmacologically activating normal myosin in a failing heart produces durable clinical benefit. That is still an open empirical question, and GALACTIC-HF's modest effect size is the honest answer so far.

COMET-HF (NCT06736574) is a Phase 3, randomized, placebo-controlled trial targeting 1,800 patients with chronic HFrEF and left ventricular ejection fraction (LVEF, the percentage of blood pumped out of the left ventricle with each beat) below 30%, on top of standard guideline-directed medical therapy [1]. That therapy baseline now routinely includes an angiotensin receptor neprilysin inhibitor (ARNi, e.g. sacubitril/valsartan), a beta-blocker, a mineralocorticoid receptor antagonist (MRA, e.g. spironolactone or eplerenone), and a sodium-glucose cotransporter 2 inhibitor (SGLT2 inhibitor, e.g. dapagliflozin or empagliflozin). The primary endpoint is time to first occurrence of a composite: cardiovascular death, heart failure event, left ventricular assist device (LVAD, a surgically implanted mechanical pump that takes over the work of a failing heart) implantation or cardiac transplantation, or stroke. Including LVAD and transplant in the composite captures severe disease progression short of death, which matters because transplant and durable mechanical support are often what sick HFrEF patients reach before dying, and counting those events gives the trial more statistical ammunition when background therapy has pushed mortality down. The enrollment design choice is the whole story. GALACTIC-HF enrolled across a broader LVEF range (<=35%) and showed a steeper benefit gradient as EF fell, with the sickest tertile driving most of the signal [2]. COMET-HF restricts enrollment to that subgroup, trading overall patient numbers for a population where the drug's mechanism should matter most. The event-driven composite is appropriate for HFrEF but creates execution risk: the trial needs enough events to power the comparison, and modern background therapy has lowered event rates meaningfully since GALACTIC-HF began. On dosing, GALACTIC-HF used pharmacokinetic-guided titration (25, 37.5, or 50 mg twice daily) with plasma concentration measurements at weeks 2 and 6 and dose adjustments at weeks 4 and 8 to keep patients within a 300 to 750 ng/mL target range [2]. Public COMET-HF materials describe LVEF <30% enrollment and the composite endpoint but do not confirm whether dosing has been simplified to a fixed regimen or continues the GALACTIC-HF PK-guided approach. This matters commercially, as discussed below. No head-to-head comparator; the comparator is placebo plus standard of care, which is the right ethical choice but means the drug must earn its label against a baseline that keeps improving.

Our model estimates a 35% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 57%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by strong earlier-phase results and larger-than-typical enrollment for this phase; it is held back by heavier-than-usual blinding and the sponsor's thin or weak approval record. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the dominant failure mode. GALACTIC-HF showed the drug works, just not strongly enough for the FDA. COMET-HF's bet is that enriching for severely reduced LVEF produces a bigger effect, but that is a post-hoc hypothesis being tested prospectively, which is exactly how enrichment strategies are supposed to work, and also exactly how they fail when the subgroup signal was noise. The direct comparator for payer and prescriber decisions is vericiguat (Verquvo, Merck), a soluble guanylate cyclase stimulator approved for HFrEF in 2021. In VICTORIA, vericiguat produced a hazard ratio of 0.90 for the composite of CV death or HF hospitalization in a broadly similar HFrEF population [12], essentially the same effect size as GALACTIC-HF's 0.92, yet vericiguat cleared the FDA while omecamtiv did not. Vericiguat also stumbled recently in VICTOR (stable HFrEF, HR 0.93, not statistically significant) [13], which argues the regulatory ceiling for incremental HFrEF add-ons is low. Vericiguat is already on formularies and in treatment algorithms. For omecamtiv to displace or add on top of that stack, COMET-HF probably needs to show a hazard ratio meaningfully below 0.85, and payers will push for a specific subpopulation argument. Safety profile is relatively clean. A dedicated QT (cardiac repolarization) study (NCT04175808) found minimal QT prolongation, and GALACTIC-HF showed no excess in ventricular arrhythmias or sudden death, which is important given the mechanism increases contractility [10]. The main on-target concern is myocardial ischemia from prolonged systole in patients with coronary disease, which was watched closely in Phase 2 and 3 without emerging as a clear signal. Execution risk centers on event rates. Background HFrEF therapy has improved substantially since GALACTIC-HF enrolled, which means COMET-HF may need longer follow-up or more patients to hit the required event count.

Worth watching, but on a long clock. COMET-HF readout is 2028 at the earliest, and the intermediate signals to track are enrollment pace, any pre-specified interim futility analysis, and whether the independent data monitoring committee recommends continuation. Specific trigger events: an interim DMC recommendation to continue, or Cytokinetics disclosing event accrual on schedule in a quarterly update. Either would suggest the trial is tracking. Four open questions worth monitoring. First, dosing: GALACTIC-HF required pharmacokinetic-guided titration with plasma concentration monitoring, which adds specialty lab infrastructure that community cardiologists do not routinely have. If COMET-HF continues PK-guided dosing, it signals that fixed dosing was not deemed safe or effective, and real-world uptake will suffer even if the trial reads out positive. If dosing was simplified to a fixed regimen, that is a meaningful commercial de-risking signal and should be confirmed in the protocol or a Cytokinetics investor update. Second, patent and regulatory exclusivity: omecamtiv's composition-of-matter patents date to the mid-2000s and have been extended by various filings, but a drug approved in 2029 or later could face a narrow commercial window before generic entry. The specific patent cliff and any new-chemical-entity exclusivity add-ons should be verified against Cytokinetics' 10-K and any Orange Book listings once approved; this writeup does not independently verify the exact expiry dates. Third, cash runway: Cytokinetics is funding both an aficamten launch and the omecamtiv confirmatory trial from roughly $200M in annual revenue plus balance sheet cash. The 10-K and 2025 8-K filings are the right place to track quarterly burn and any dilutive financings [5][11]. Fourth, the vericiguat comparison is the commercial reality check. Vericiguat delivered HR 0.90 and is on formularies; omecamtiv needs HR materially better than that at a premium price to earn adoption. Cytokinetics itself is more interesting than this single asset. Aficamten's commercial ramp in obstructive HCM is where the stock will trade in the near term, and omecamtiv is an optionality call on top of that. Check back in Q2 2027 for an enrollment completion update, and set a hard calendar reminder for the readout window. If GALACTIC-HF's result could not clear the FDA bar, COMET-HF needs to produce something materially better. That is the specific question the trial exists to answer, and it is the only question that matters commercially.

Patent expiry dates for omecamtiv mecarbil were not independently verified for this writeup and should be checked against Cytokinetics' most recent 10-K and USPTO filings before any commercial-window conclusions are drawn.